유전체학 데이터 분석 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 기술별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Genomics Data Analysis Market Summary

The global genomics data analysis market size was estimated at USD 5.68 billion in 2024 and is projected to reach USD 20.49 billion by 2033, growing at a CAGR of 15.40% from 2025 to 2033. This growth trajectory reflects the accelerating adoption of next-generation sequencing (NGS), the expanding use of precision medicine, and the rising demand for cloud-based bioinformatics platforms.

More public and private sector investments and incorporating artificial intelligence (AI) and machine learning (ML) into genomic processes will help support additional market growth.

Global Genomics Data Analysis Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global genomics data analysis market based on service, technology, application, end use, and region:

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Data Preprocessing and Quality Control
• Variant Calling and Annotation
• Gene Expression Analysis
• Data Interpretation and Reporting
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Next-Generation Sequencing (NGS)
• Microarray
• PCR
• CRISPR-based Analysis
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostics
• Drug Discovery & Development
  • Oncology
  • Neurology
  • Infectious Diseases
  • Others
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals & Labs
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Service
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Impact Analysis
    • 3.3.1.1. AI & machine learning integration
    • 3.3.1.2. Explosion of Genomic Data
  • 3.3.2. Market Restraint Impact Analysis
    • 3.3.2.1. High cost of genomic analysis infrastructure
    • 3.3.2.2. Data privacy & security concerns
• 3.4. Business Environment Analysis
  • 3.4.1. PESTLE Analysis
  • 3.4.2. PORTER'S Five Forces Analysis

Chapter 4. Service Business Analysis

• 4.1. Service Segment Dashboard
• 4.2. Global Genomics Data Analysis Market Service, Movement Analysis
• 4.3. Global Genomics Data Analysis Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
• 4.4. Data Preprocessing and Quality Control
  • 4.4.1. Global data preprocessing and quality control market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Variant Calling and Annotation
  • 4.5.1. Global variant calling and annotation market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Gene Expression Analysis
  • 4.6.1. Global gene expression analysis market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Data Interpretation and Reporting
  • 4.7.1. Global data interpretation and reporting market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Global others media market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Global Genomics Data Analysis Market Technology, Movement Analysis
• 5.3. Global Genomics Data Analysis Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 5.4. Next-Generation Sequencing (NGS)
  • 5.4.1. Global next-generation sequencing (NGS) market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Microarray
  • 5.5.1. Global microarray market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. PCR
  • 5.6.1. Global PCR market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. CRISPR-based Analysis
  • 5.7.1. Global CRISPR-based analysis market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global Genomics Data Analysis Market Application, Movement Analysis
• 6.3. Global Genomics Data Analysis Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Diagnostics
  • 6.4.1. Global diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Drug Discovery & Development
  • 6.5.1. Global drug discovery & development market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.1. Oncology
      • 6.5.1.1.1. Global oncology market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.2. Neurology
      • 6.5.1.2.1. Global neurology market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.3. Infectious Diseases
      • 6.5.1.3.1. Global infectious diseases market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.4. Others
      • 6.5.1.4.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Genomics Data Analysis Market End Use, Movement Analysis
• 7.3. Global Genomics Data Analysis Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Academic & Research Institutes
  • 7.4.1. Global academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Pharmaceutical & Biotechnology Companies
  • 7.5.1. Global pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Hospitals & Labs
  • 7.6.1. Global hospitals & labs market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Genomics Data Analysis Market: Regional Estimates and Trend Analysis, by Service, Technology, Application, & End Use

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 8.3. North America
  • 8.3.1. North America genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. U.S. genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Canada genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Mexico genomics data analysis market, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. UK genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Germany genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. France genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Italy genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Spain genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Denmark genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Target Disease Prevalence
    • 8.4.8.3. Competitive Scenario
    • 8.4.8.4. Regulatory Framework
    • 8.4.8.5. Sweden genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Target Disease Prevalence
    • 8.4.9.3. Competitive Scenario
    • 8.4.9.4. Regulatory Framework
    • 8.4.9.5. Norway genomics data analysis market, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Japan genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. China genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. India genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Competitive Scenario
    • 8.5.5.4. Regulatory Framework
    • 8.5.5.5. Australia genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Competitive Scenario
    • 8.5.6.4. Regulatory Framework
    • 8.5.6.5. Thailand genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Competitive Scenario
    • 8.5.7.4. Regulatory Framework
    • 8.5.7.5. South Korea genomics data analysis market, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Brazil genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Argentina genomics data analysis market, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Competitive Scenario
    • 8.7.2.4. Regulatory Framework
    • 8.7.2.5. South Africa genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Competitive Scenario
    • 8.7.3.4. Regulatory Framework
    • 8.7.3.5. Saudi Arabia genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Target Disease Prevalence
    • 8.7.4.3. Competitive Scenario
    • 8.7.4.4. Regulatory Framework
    • 8.7.4.5. UAE genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Target Disease Prevalence
    • 8.7.5.3. Competitive Scenario
    • 8.7.5.4. Regulatory Framework
    • 8.7.5.5. Kuwait genomics data analysis market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Illumina, Inc.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Service Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. QIAGEN
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Service Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. CD Genomics
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Service Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. CellCarta
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Service Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Charles River Laboratories
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Service Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. BGI
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Service Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Fios Genomics
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Service Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Eurofins Genomics
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Service Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Basepair
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Service Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Golden Helix
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Service Benchmarking
    • 9.4.10.4. Strategic Initiatives